Latest Breaking News On - Phosplatin therapeutics inc - Page 1 : comparemela.com

Phosplatin Therapeutics Appoints Lorenzo Galluzzi, PhD, a Pioneer in Immunogenic Cell Death Research, to Scientific Advisory Board

Phosplatin Therapeutics Appoints Lorenzo Galluzzi, PhD, a Pioneer in Immunogenic Cell Death Research, to Scientific Advisory Board - read this article along with other careers information, tips and advice on BioSpace

United statesNew yorkFrance generalRobert fallonMark corbaeStephanie carringtonWeil cornellTaylorb youngLorenzo galluzziGustave roussy comprehensive cancer centerWeill cornell medical collegeMerck kgaGalluzzi labLab timesEuropean academy for tumor immunologyUniversity paris sud

Phosplatin Therapeutics Appoints Lorenzo Galluzzi, PhD, a Pioneer in Immunogenic Cell Death Research, to Scientific Advisory Board

/PRNewswire/ Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced the appointment of.

United statesNew yorkFrance generalRobert fallonMark corbaeStephanie carringtonWeil cornellTaylorb youngLorenzo galluzziGustave roussy comprehensive cancer centerWeill cornell medical collegeMerck kgaGalluzzi labLab timesEuropean academy for tumor immunologyUniversity paris sud

Phosplatin Therapeutics Appoints Sebastian Guth, PhD, to Board of Directors

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesBrooke raphaelRobert fallonMark corbaeStephanie carringtonSebastian guthBayer pharmaceuticalsPhosplatin therapeutics incBiotechnology innovation organizationBoard of the pharmaceutical researchBayer pharmaceuticals americasMerck kgaMerck kgaaPrnewswire phosplatin therapeutics incTherapeutics incAmericas region

Phosplatin Therapeutics Announces $37 Million Series A Financing

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesSan franciscoBrooke raphaelRobert fallonNeil sunderlandMark corbaeStephanie carringtonPhosplatin therapeutics incMerck kgaMerck kgaaPrnewswire phosplatin therapeutics incVirtual congressTherapeutics incChief executive officerPhosplatin therapeuticsMontreux growth partners

Phosplatin Therapeutics Reports Phase 1b Study Results of Immunogenic Cell Death Inducer PT-112 Plus PD-L1 Inhibitor avelumab in Metastatic Prostate Cancer at ASCO Annual Meeting

Phosplatin Therapeutics Reports Phase 1b Study Results of Immunogenic Cell Death Inducer PT-112 Plus PD-L1 Inhibitor avelumab in Metastatic Prostate Cancer at ASCO Annual Meeting
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesAlanh bryceMark corbaeStephanie carringtonJosephf odonnellTaylorb youngPhosplatin therapeutics incMeeting libraryMerck kgaMerck kgaaPrnewswire phosplatin therapeutics incVirtual congressStrategic developmentTherapeutics incChief operatingChief medical officer